Nothing said here yet.
to join the conversation.
| Dash Barry HDirector | Buy | 100,000 | $26.0K | Fri, Oct 9 |
| Dash Barry HDirector | Buy | 30,000 | $8.6K | Wed, Aug 19 |
ELTP and AYTU have different CNS portfolios, growth drivers and valuations, but which pharmaceutical stock looks better positioned? Let's dive in.
Elite Pharmaceuticals' downgrade to Neutral cites pricing pressure, weaker revenue and margins, and limited visibility into new-product contributions.
Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
ELTP's first-quarter fiscal 2027 revenues decline as generic competition and lower pricing offset higher volumes, while pipeline development remains a growth focus.
Elite Pharmaceuticals Inc (ELTP) reports stable Q1 FY2027 results with robust cash flow and a promising pipeline, while navigating market pricing pressures and advancing its Nasdaq uplisting plans.
Elite Pharmaceuticals (OTCMKTS:ELTP) reported first-quarter fiscal 2027 revenue of $32.4 million and operating profit of $7.5 million, with Chief Financial Officer Carter Ward describing both measures as steady and consistent with the preceding three quarters.
Conference Call Scheduled for Friday, August 14, 2026 at 11:30 AM EDTNorthvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc.
Financials for First Quarter of Fiscal Year 2027 Ended June 30, 2026 will be released on Thursday, August 13, 2026Northvale, New Jersey--(Newsfile Corp. - August 10, 2026) - Elite Pharmaceuticals, Inc.
Northvale, New Jersey--(Newsfile Corp. - August 4, 2026) - Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals and Cumberland Pharmaceuticals follow different growth paths, but which looks more compelling now? Let's dive in.